Kerem Can Yilmaz

Plasma osteopontin concentration is elevated in patients with coronary bare metal stent restenosis

Abstract Objective: Osteopontin is a component of atherosclerotic lesions, secreted by monocytes, macrophages and endothelial and vascular smooth muscle cells, which together are responsible for neointimal proliferation. We examined whether elevated plasma osteopontin concentration was associated with in-stent restenosis in patients with coronary artery disease. Subjects and methods: We enrolled 91 patients who underwent coronary artery stenting, and 60 control patients with normal findings on coronary angiography, between June 2012 and September 2013. For patients with stents, we measured plasma osteopontin concentration at the first follow-up coronary angiogram. For controls, plasma osteopontin concentration was measured at the time of angiography. Results: Of the 91 patients who had undergone coronary artery stenting, 31 (34.1%) had developed in-stent restenosis and the mean time passed to control coronary angiography was 36.7 months (±SD 35.1 months). Mean plasma osteopontin concentration in this group was 2721.4 ± 1787.8 pg/ml, significantly higher than the 60 patients (65.9%) with no in-stent restenosis (1770.4 ± 1208.2 pg/ml, p = .011) and the 60 patients with a normal coronary angiogram (1572.4 ± 904.8 pg/ml, p = .002). There was no significant difference in mean osteopontin concentration between the patients with no in-stent restenosis and the control group (p = .312). Conclusions: Elevated plasma osteopontin concentration is associated with in-stent stenosis in patients with coronary artery disease. Further studies will be needed to establish whether osteopontin can predict in-stent restenosis and guide clinical management strategies.

OP-023 THE EFFECTS OF ORAL IMMUNOSUPPRESSIVE AGENTS UPON BARE METAL CORONARY ARTERY STENTS IN RENAL TRANSPLANT RECIPIENTS

61%, the observed FFR values decreased with advancing lesion cathegory (p = 0.041). However observed FFR values did not differ between the patients with MS and without MS in each category (P = 0.822, p = 0.943, p = 0.899 respectively) (Table 1). Conclusions: In this study we evaluate the possible impact of MS on FFR measurement by comparing FFR values in similar lesions. MS has no significant effect of FFR which has an important role in hemodynamic evaluation of coronary lesions. This study provides additional data for the reliability of FFR in patients with MS.

OP-143 THE EVALUATION OF ROSUVASTATIN TREATMENT EFFECT ON FASTING AND NON FASTING TRIGLYCERIDE LEVELS

However, the levels of LDL (p=0.01), triglyceride (p=0.001) and cholesterol (p=0.02) were significantly higher in PAI-1 4G/4G group. Conclusions: PAI-1 is a characteristic biological example of how complicated and unpredictable could be the influence of the same enzyme on different tissues or organs. Our findings suggest that the 4G/4G polymorphism of the PAI-1 gene might be associated with LDL particle size in healthy Turkish population. Therefore, evaluation of the PAI-1 gene in hyperlipidemic population will help clarify etiology and prognosis of the disease.

OP-144 THE EVALUATION OF EFFECT OF ROSUVASTATIN TREATMENT IN MALES AND FEMALES ON FASTING AND NON FASTING TRIGLYCERIDE LEVELS

However, the levels of LDL (p=0.01), triglyceride (p=0.001) and cholesterol (p=0.02) were significantly higher in PAI-1 4G/4G group. Conclusions: PAI-1 is a characteristic biological example of how complicated and unpredictable could be the influence of the same enzyme on different tissues or organs. Our findings suggest that the 4G/4G polymorphism of the PAI-1 gene might be associated with LDL particle size in healthy Turkish population. Therefore, evaluation of the PAI-1 gene in hyperlipidemic population will help clarify etiology and prognosis of the disease.